Hepatic fibrosis 2006: Report of the third AASLD Single Topic Conference
โ Scribed by Scott L. Friedman; Don C. Rockey; D. Montgomery Bissell
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 117 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
The third American Associated for the Study of Liver Diseases (AASLD)-sponsored Single Topic Conference on hepatic fibrosis was held in June 2006. The conference was both international, with 6 countries represented, and cross-disciplinary, linking the basic molecular and cellular biology of fibrogenic cells to clinical trial design for emerging antifibrotic therapies. The specific goals of the conference were: (1) to consolidate knowledge about the natural history of fibrosis;
(2) to clarify potential endpoints and markers; (3) to emphasize new antifibrotic targets developed on the basis of advances in basic science; and (4) to understand current critical issues pertaining to clinical trial design. Given the tremendous growth of the field and the constraints of a 2-day format, the selection of speakers was a challenge. A number of topics not included in the oral presentations were featured at poster sessions, lending breadth and depth to the meeting as a whole. Surprising new themes emerged about molecular, clinical, and regulatory aspects of the field, and a consensus emerged that hepatic fibrosis has matured into an integrated discipline that promises to significantly improve the prognosis of patients with fibrosing liver disease.
๐ SIMILAR VOLUMES
Blood flow and vascular resistance in the hepatic vasculature are closely regulated through a balance of vasoactive molecules including nitric oxide (NO), carbon monoxide (CO), endothelin (ET), and prostanoids such as prostacyclin. These vasoregulatory agents interact with unique nonparenchymal cell
hronic hepatitis C virus (HCV) infection affects a large number of patients worldwide. While our current therapies (Table ) are effective in approximately 50% of patients, therapy is costly, prolonged, and associated with significant side effects, and it is not suitable for certain groups of patient
and Roche and has received grants from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Roche, and Merck. David Thomas has been a consultant for Merck and has received grants from Gilead and Merck. Hashem El-Serag has been a consultant for Vertex and has received grants from Bayer and Abbott. Ray Kim